Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KLBiochem. Biophys. Res. Commun. 2013-04-10.

eIF4E3, a new actor in mRNA metabolism and tumor suppression.Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KLCell Cycle 2013-04-09;12(8).

Aiding and abetting cancer: mRNA export and the nuclear pore.Culjkovic-Kraljacic B, Borden KLTrends Cell Biol. 2013-04-09.

The Oncogene eIF4E: Using Biochemical Insights to Target Cancer.Carroll M, Borden KLJ. Interferon Cytokine Res. 2013-03-08.

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in Acute Myeloid Leukemia.Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Holm Nielsen T, Hiscott J, Mann KK, Borden KLLeukemia 2013-03-07.

eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden KLProc. Natl. Acad. Sci. U.S.A. 2013-02-19.

Mechanisms and insights into drug resistance in cancer.Zahreddine H, Borden KLFront Pharmacol 2013-01-01;4:28.

MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo.Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick ACancer Cell 2012-12-11;22(6):812-24.

The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation.Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KLCell Rep 2012-08-14.

RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden KL, Meloche S, Roux PPOncogene 2012-07-16.